Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review

Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are asso...

Full description

Bibliographic Details
Published in:Asian Pacific Journal of Tropical Medicine
Main Authors: Soumya Ranjan Satapathy, Rudra Narayan Sahoo
Format: Article in Journal/Newspaper
Language:English
Published: Wolters Kluwer Medknow Publications 2022
Subjects:
visceral leishmaniasis
doxorubicin
passive targeting
repositioning
non-pegylated liposome encapsulated doxorubicin
resistance
Arctic medicine. Tropical medicine
RC955-962
Arctic
Azar
Online Access:https://doi.org/10.4103/1995-7645.348156
https://doaj.org/article/ba9ebd244fc64526a063852cb1d45445

Similar Items